Yichi Xu,Bo Wen,Dai Zhang et al.
Yichi Xu et al.
Patrick Y Muller,Johannes Eisinger,Pakeeza Sayyed et al.
Patrick Y Muller et al.
Purpose of review: Most novel anti-cancer therapies involve combining multiple immuno-oncology and/or targeted drugs. The historical paradigm of exploring combination regimens only after approval of the individual drugs i...
Artificial Intelligence in Lung Cancer: From Early Detection to Personalized Therapy [0.03%]
人工智能在肺癌领域：从早期检测到个性化治疗
Daniel Fu,Durga V Sritharan,Rahul D&#x;Souza et al.
Daniel Fu et al.
Polypharmacy, Medicine Optimisation, and Medication Adherence in Older Cancer Patients [0.03%]
老年癌症患者的多重用药、药物优化和用药依从性
Abu Saleh Md Taher,Vanya Slavova-Boneva,Nicolò Matteo Luca Battisti
Abu Saleh Md Taher
Radiotherapy for Meningiomas: Molecular, Imaging, and Therapeutic Advances [0.03%]
脑膜瘤放射治疗的分子、影像和治疗进展
Bradley Eckelmann,Brett Morris
Bradley Eckelmann
Purpose of review: Treatment of meningioma is rapidly evolving, as molecular classification, functional imaging, and radiotherapeutic techniques have undergone recent advances. The purpose of this review is to integrate these developments w...
Imaging as a Driver of Multidisciplinary Decision-making in Neuroendocrine Neoplasms: A Targeted Evidence Synthesis [0.03%]
神经内分泌肿瘤多学科决策的影像驱动：目标证据综合
Milin Patel,Kiven Vuong,Bipin Nanda et al.
Milin Patel et al.
Harnessing Proteogenomics to Advance Precision Oncology: From Melanoma and Hepatocellular Carcinoma Perspective [0.03%]
利用蛋白质基因组学推进精准肿瘤学：以黑色素瘤和肝细胞癌为例视角
Abolaji Samson Olagunju,Ayoade Desmond Babalola,Sarah Eseroghene Najophe et al.
Abolaji Samson Olagunju et al.
Purpose of Review: Genomic profiling has significantly advanced precision oncology; however, relying solely on genome-driven approaches is often insufficient to capture the full molecular complexity of cancer. Proteogenom...
Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC) [0.03%]
EGFR突变型非小细胞肺癌的治疗进展
Abhinav Vyas,Won Jin Jeon,Sanad Alhushki et al.
Abhinav Vyas et al.
Purpose of Review: With the approvals of various targeted therapies including tyrosine kinase inhibitors to antibody–drug conjugates, the treatment landscape of patients with EGFR-mutant non-small cell lung cancer has dr...
Deprescribing for Comorbidities in Patients with Cancer - a Systematic Review [0.03%]
针对肿瘤合并症患者的减药治疗——系统性综述
Inês Agonia,Marina Cruz,André Ponte
Inês Agonia